Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL92069 | 0.98 | ALDH1A1 (0.59) | ALDH1A1MAPTKMT2AMEN1THRB | |
| SCHEMBL29565516 | 0.98 | ALDH1A1 (0.59) | ALDH1A1MAPTKMT2AMEN1THRB | |
| SCHEMBL167787 | 0.83 | ALDH1A1 (0.52) | ALDH1A1MAPTKMT2AMEN1THRB | |
| Hydrochloric Acid SCHEMBL365098 | 0.83 | ALDH1A1 (0.61) | ALDH1A1MAPTKMT2AMEN1THRB | |
| SCHEMBL27952329 | 0.82 | ALDH1A1 (0.53) | ALDH1A1MAPTKMT2AMEN1THRB | |
| SCHEMBL29811646 | 0.80 | ALDH1A1 (0.61) | ALDH1A1KDM4ESMN1; SMN2CYP3A4GAA | |
| SCHEMBL171279 | 0.80 | ALDH1A1 (0.61) | ALDH1A1KDM4ESMN1; SMN2CYP3A4GAA | |
| SCHEMBL5863619 | 0.79 | MAPT (0.73) | ALDH1A1MAPTKMT2AMEN1KDM4E | |
| SCHEMBL24750329 | 0.79 | ALDH1A1 (0.61) | ALDH1A1MAPTKMT2AMEN1THRB | |
| SCHEMBL11409091 | 0.79 | MAPT (0.77) | ALDH1A1MAPTKMT2AMEN1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10123978-B2 | Patch for treating dermatophytosis | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-11-13 | — | — | US | disclosed |
| EP-2881114-B1 | ANTI-TRICHOPHYTIC ADHESIVE PATCH | MEIJI SEIKA PHARMA CO LTD (JP) | 2018-09-05 | — | — | EP | disclosed |
| US-20180200199-A1 | PATCH FOR TREATING DERMATOPHYTOSIS | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-07-19 | — | — | US | disclosed |
| US-20150209301-A1 | PATCH FOR ANTI-DERMATOPHYTOSIS | NICHIBAN COMPANY LIMITED (JP) | 2015-07-30 | — | — | US | disclosed |
| EP-2889031-A1 | ANTITRICHOPHYTOSIS SOLUTION FOR EXTERNAL USE | Meiji Seika Pharma Co., Ltd. (JP) | 2015-07-01 | — | — | EP | disclosed |
| EP-2881114-A1 | ANTI-TRICHOPHYTIC ADHESIVE PATCH | Meiji Seika Pharma Co., Ltd. (JP) | 2015-06-10 | — | — | EP | disclosed |
| EP-2593432-B1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LTD (GB) | 2014-10-22 | — | — | EP | disclosed |
| US-20140030209-A1 | TOPICAL LIQUID AGENT FOR THE TREATMENT OF DERMATOPHYTOSIS | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8592629-B2 | Sulfonamide derivatives as Nav 1.7 inhibitors | PFIZER LIMITED (GB) | 2013-11-26 | — | — | US | disclosed |
| CN-103339112-A | Topical antifungal agent | MEIJI SEIKA PHARMA CO LTD | 2013-10-02 | — | — | CN | disclosed |
| EP-0910358-A1 | PHENYL DERIVATIVES USEFUL AS BLOCKERS OF CHLORIDE CHANNELS | NEUROSEARCH A/S (DK) | 1999-04-28 | — | — | EP | disclosed |
| EP-0693053-B1 | UREA AND AMIDE DERIVATIVES AND THEIR USE IN THE CONTROL OF CELL MEMBRANE POTASSIUM CHANNELS | NEUROSEARCH AS (DK) | 1999-01-20 | — | — | EP | disclosed |
| US-5696138-A | Urea derivatives and their use | NEUROSEARCH A/S (DK) | 1997-12-09 | — | — | US | disclosed |
| WO-1997045111-A1 | PHENYL DERIVATIVES USEFUL AS BLOCKERS OF CHLORIDE CHANNELS | NEUROSEARCH A/S (DK) | 1997-12-04 | — | — | WO | disclosed |
| EP-0693053-A1 | UREA AND AMIDE DERIVATIVES AND THEIR USE IN THE CONTROL OF CELL MEMBRANE POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 1996-01-24 | — | — | EP | disclosed |
| WO-1994022807-A1 | UREA AND AMIDE DERIVATIVES AND THEIR USE IN THE CONTROL OF CELL MEMBRANE POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 1994-10-13 | — | — | WO | disclosed |
| EP-0225175-A2 | Dihydropyridine derivatives, processes for their preparation and pharmaceutical compositions thereof | FISONS plc (GB) | 1987-06-10 | — | — | EP | disclosed |
| US-4224025-A | Process for the dyeing and printing of paper materials in different hues using a single coupling component | CIBA-GEIGY CORPORATION (US) | 1980-09-23 | — | — | US | disclosed |
| US-4165967-A | HYDROXY-PYRIDINE OR PYRIDONE COUPLERS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1979-08-28 | — | — | US | disclosed |
| US-4065254-A | DIAZO DYES, LEATHER, COTTON, WOOL | CIBA-GEIGY CORPORATION (US) | 1977-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180200199-A1 | PATCH FOR TREATING DERMATOPHYTOSIS | DPM1, KRT18, LCP1 | GAA 4547/4885ALDH1A1 3414/4885MAPT 1160/4885 |
| US-10123978-B2 | Patch for treating dermatophytosis | DPM1, KRT18, LCP1 | GAA 4547/4885ALDH1A1 3414/4885MAPT 1160/4885 |
| US-20140030209-A1 | TOPICAL LIQUID AGENT FOR THE TREATMENT OF DERMATOPHYTOSIS | POLR1C, CUTA, C1R | GAA 4050/4885ALDH1A1 2643/4885MAPT 3385/4885 |
| US-20150209301-A1 | PATCH FOR ANTI-DERMATOPHYTOSIS | CUTA, NACA, POLR1C | GAA 4680/4885ALDH1A1 3696/4885MAPT 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.